
    
      This is a single-arm study of patients who plan on starting brigatinib 90 mg QD or brigatinib
      90 mg QD x 7 days to brigatinib 180 mg QD. Participants who enroll on this study protocol
      will either be taking brigatinib in the context of an ongoing clinical trial, or as part of
      standard of care treatment as licensed by FDA.
    
  